The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Oncology Biosimilars Market Research Report 2025

Global Oncology Biosimilars Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1971978

No of Pages : 86

Ask Your Query

Synopsis

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

The global Oncology Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Oncology Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Biosimilars.

Report Scope

The Oncology Biosimilars market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oncology Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company (Partial List):

  • Celltrion
  • Biocon
  • Dr. Reddy’s Laboratories
  • STADA Arzneimittel AG
  • Intas Pharmaceuticals
  • Pfizer
  • Sandoz International
  • Teva Pharmaceutical Industries Ltd
  • Apotex
  • BIOCAD

Segment by Type

  • Monoclonal Antibody
  • Hematopoietic Agents
  • G-CSF
  • Others

Segment by Application

  • Retail Pharmacies
  • Hospital Pharmacy
  • Online Pharmacy

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Biosimilars Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibody
1.2.3 Hematopoietic Agents
1.2.4 G-CSF
1.2.5 Others
1.3 Market by Application
1.3.1 Global Oncology Biosimilars Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Biosimilars Market Perspective (2019-2030)
2.2 Oncology Biosimilars Growth Trends by Region
2.2.1 Global Oncology Biosimilars Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncology Biosimilars Historic Market Size by Region (2019-2024)
2.2.3 Oncology Biosimilars Forecasted Market Size by Region (2025-2030)
2.3 Oncology Biosimilars Market Dynamics
2.3.1 Oncology Biosimilars Industry Trends
2.3.2 Oncology Biosimilars Market Drivers
2.3.3 Oncology Biosimilars Market Challenges
2.3.4 Oncology Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Biosimilars Players by Revenue
3.1.1 Global Top Oncology Biosimilars Players by Revenue (2019-2024)
3.1.2 Global Oncology Biosimilars Revenue Market Share by Players (2019-2024)
3.2 Global Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Biosimilars Revenue
3.4 Global Oncology Biosimilars Market Concentration Ratio
3.4.1 Global Oncology Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Biosimilars Revenue in 2023
3.5 Oncology Biosimilars Key Players Head office and Area Served
3.6 Key Players Oncology Biosimilars Product Solution and Service
3.7 Date of Enter into Oncology Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Biosimilars Breakdown Data by Type
4.1 Global Oncology Biosimilars Historic Market Size by Type (2019-2024)
4.2 Global Oncology Biosimilars Forecasted Market Size by Type (2025-2030)
5 Oncology Biosimilars Breakdown Data by Application
5.1 Global Oncology Biosimilars Historic Market Size by Application (2019-2024)
5.2 Global Oncology Biosimilars Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncology Biosimilars Market Size (2019-2030)
6.2 North America Oncology Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oncology Biosimilars Market Size by Country (2019-2024)
6.4 North America Oncology Biosimilars Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Biosimilars Market Size (2019-2030)
7.2 Europe Oncology Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oncology Biosimilars Market Size by Country (2019-2024)
7.4 Europe Oncology Biosimilars Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Biosimilars Market Size (2019-2030)
8.2 Asia-Pacific Oncology Biosimilars Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oncology Biosimilars Market Size by Region (2019-2024)
8.4 Asia-Pacific Oncology Biosimilars Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Biosimilars Market Size (2019-2030)
9.2 Latin America Oncology Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oncology Biosimilars Market Size by Country (2019-2024)
9.4 Latin America Oncology Biosimilars Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Biosimilars Market Size (2019-2030)
10.2 Middle East & Africa Oncology Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oncology Biosimilars Market Size by Country (2019-2024)
10.4 Middle East & Africa Oncology Biosimilars Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celltrion
11.1.1 Celltrion Company Detail
11.1.2 Celltrion Business Overview
11.1.3 Celltrion Oncology Biosimilars Introduction
11.1.4 Celltrion Revenue in Oncology Biosimilars Business (2019-2024)
11.1.5 Celltrion Recent Development
11.2 Biocon
11.2.1 Biocon Company Detail
11.2.2 Biocon Business Overview
11.2.3 Biocon Oncology Biosimilars Introduction
11.2.4 Biocon Revenue in Oncology Biosimilars Business (2019-2024)
11.2.5 Biocon Recent Development
11.3 Dr. Reddy’s Laboratories
11.3.1 Dr. Reddy’s Laboratories Company Detail
11.3.2 Dr. Reddy’s Laboratories Business Overview
11.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Introduction
11.3.4 Dr. Reddy’s Laboratories Revenue in Oncology Biosimilars Business (2019-2024)
11.3.5 Dr. Reddy’s Laboratories Recent Development
11.4 STADA Arzneimittel AG
11.4.1 STADA Arzneimittel AG Company Detail
11.4.2 STADA Arzneimittel AG Business Overview
11.4.3 STADA Arzneimittel AG Oncology Biosimilars Introduction
11.4.4 STADA Arzneimittel AG Revenue in Oncology Biosimilars Business (2019-2024)
11.4.5 STADA Arzneimittel AG Recent Development
11.5 Intas Pharmaceuticals
11.5.1 Intas Pharmaceuticals Company Detail
11.5.2 Intas Pharmaceuticals Business Overview
11.5.3 Intas Pharmaceuticals Oncology Biosimilars Introduction
11.5.4 Intas Pharmaceuticals Revenue in Oncology Biosimilars Business (2019-2024)
11.5.5 Intas Pharmaceuticals Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Oncology Biosimilars Introduction
11.6.4 Pfizer Revenue in Oncology Biosimilars Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Sandoz International
11.7.1 Sandoz International Company Detail
11.7.2 Sandoz International Business Overview
11.7.3 Sandoz International Oncology Biosimilars Introduction
11.7.4 Sandoz International Revenue in Oncology Biosimilars Business (2019-2024)
11.7.5 Sandoz International Recent Development
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Teva Pharmaceutical Industries Ltd Company Detail
11.8.2 Teva Pharmaceutical Industries Ltd Business Overview
11.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Introduction
11.8.4 Teva Pharmaceutical Industries Ltd Revenue in Oncology Biosimilars Business (2019-2024)
11.8.5 Teva Pharmaceutical Industries Ltd Recent Development
11.9 Apotex
11.9.1 Apotex Company Detail
11.9.2 Apotex Business Overview
11.9.3 Apotex Oncology Biosimilars Introduction
11.9.4 Apotex Revenue in Oncology Biosimilars Business (2019-2024)
11.9.5 Apotex Recent Development
11.10 BIOCAD
11.10.1 BIOCAD Company Detail
11.10.2 BIOCAD Business Overview
11.10.3 BIOCAD Oncology Biosimilars Introduction
11.10.4 BIOCAD Revenue in Oncology Biosimilars Business (2019-2024)
11.10.5 BIOCAD Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Oncology Biosimilars Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Monoclonal Antibody
Table 3. Key Players of Hematopoietic Agents
Table 4. Key Players of G-CSF
Table 5. Key Players of Others
Table 6. Global Oncology Biosimilars Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Oncology Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Oncology Biosimilars Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Oncology Biosimilars Market Share by Region (2019-2024)
Table 10. Global Oncology Biosimilars Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Oncology Biosimilars Market Share by Region (2025-2030)
Table 12. Oncology Biosimilars Market Trends
Table 13. Oncology Biosimilars Market Drivers
Table 14. Oncology Biosimilars Market Challenges
Table 15. Oncology Biosimilars Market Restraints
Table 16. Global Oncology Biosimilars Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Oncology Biosimilars Market Share by Players (2019-2024)
Table 18. Global Top Oncology Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2023)
Table 19. Ranking of Global Top Oncology Biosimilars Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Oncology Biosimilars Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Oncology Biosimilars Product Solution and Service
Table 23. Date of Enter into Oncology Biosimilars Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Oncology Biosimilars Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Oncology Biosimilars Revenue Market Share by Type (2019-2024)
Table 27. Global Oncology Biosimilars Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Oncology Biosimilars Revenue Market Share by Type (2025-2030)
Table 29. Global Oncology Biosimilars Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Oncology Biosimilars Revenue Market Share by Application (2019-2024)
Table 31. Global Oncology Biosimilars Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Oncology Biosimilars Revenue Market Share by Application (2025-2030)
Table 33. North America Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Oncology Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Oncology Biosimilars Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Oncology Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Oncology Biosimilars Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Oncology Biosimilars Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Oncology Biosimilars Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Oncology Biosimilars Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Oncology Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oncology Biosimilars Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Oncology Biosimilars Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Oncology Biosimilars Market Size by Country (2025-2030) & (US$ Million)
Table 48. Celltrion Company Detail
Table 49. Celltrion Business Overview
Table 50. Celltrion Oncology Biosimilars Product
Table 51. Celltrion Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 52. Celltrion Recent Development
Table 53. Biocon Company Detail
Table 54. Biocon Business Overview
Table 55. Biocon Oncology Biosimilars Product
Table 56. Biocon Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 57. Biocon Recent Development
Table 58. Dr. Reddy’s Laboratories Company Detail
Table 59. Dr. Reddy’s Laboratories Business Overview
Table 60. Dr. Reddy’s Laboratories Oncology Biosimilars Product
Table 61. Dr. Reddy’s Laboratories Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 62. Dr. Reddy’s Laboratories Recent Development
Table 63. STADA Arzneimittel AG Company Detail
Table 64. STADA Arzneimittel AG Business Overview
Table 65. STADA Arzneimittel AG Oncology Biosimilars Product
Table 66. STADA Arzneimittel AG Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 67. STADA Arzneimittel AG Recent Development
Table 68. Intas Pharmaceuticals Company Detail
Table 69. Intas Pharmaceuticals Business Overview
Table 70. Intas Pharmaceuticals Oncology Biosimilars Product
Table 71. Intas Pharmaceuticals Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 72. Intas Pharmaceuticals Recent Development
Table 73. Pfizer Company Detail
Table 74. Pfizer Business Overview
Table 75. Pfizer Oncology Biosimilars Product
Table 76. Pfizer Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Sandoz International Company Detail
Table 79. Sandoz International Business Overview
Table 80. Sandoz International Oncology Biosimilars Product
Table 81. Sandoz International Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 82. Sandoz International Recent Development
Table 83. Teva Pharmaceutical Industries Ltd Company Detail
Table 84. Teva Pharmaceutical Industries Ltd Business Overview
Table 85. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product
Table 86. Teva Pharmaceutical Industries Ltd Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 87. Teva Pharmaceutical Industries Ltd Recent Development
Table 88. Apotex Company Detail
Table 89. Apotex Business Overview
Table 90. Apotex Oncology Biosimilars Product
Table 91. Apotex Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 92. Apotex Recent Development
Table 93. BIOCAD Company Detail
Table 94. BIOCAD Business Overview
Table 95. BIOCAD Oncology Biosimilars Product
Table 96. BIOCAD Revenue in Oncology Biosimilars Business (2019-2024) & (US$ Million)
Table 97. BIOCAD Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncology Biosimilars Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Oncology Biosimilars Market Share by Type: 2023 VS 2030
Figure 3. Monoclonal Antibody Features
Figure 4. Hematopoietic Agents Features
Figure 5. G-CSF Features
Figure 6. Others Features
Figure 7. Global Oncology Biosimilars Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Oncology Biosimilars Market Share by Application: 2023 VS 2030
Figure 9. Retail Pharmacies Case Studies
Figure 10. Hospital Pharmacy Case Studies
Figure 11. Online Pharmacy Case Studies
Figure 12. Oncology Biosimilars Report Years Considered
Figure 13. Global Oncology Biosimilars Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Oncology Biosimilars Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Oncology Biosimilars Market Share by Region: 2023 VS 2030
Figure 16. Global Oncology Biosimilars Market Share by Players in 2023
Figure 17. Global Top Oncology Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Oncology Biosimilars Revenue in 2023
Figure 19. North America Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Oncology Biosimilars Market Share by Country (2019-2030)
Figure 21. United States Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Oncology Biosimilars Market Share by Country (2019-2030)
Figure 25. Germany Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Oncology Biosimilars Market Share by Region (2019-2030)
Figure 33. China Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Oncology Biosimilars Market Share by Country (2019-2030)
Figure 41. Mexico Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Oncology Biosimilars Market Share by Country (2019-2030)
Figure 45. Turkey Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Oncology Biosimilars Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Celltrion Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 48. Biocon Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 49. Dr. Reddy’s Laboratories Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 50. STADA Arzneimittel AG Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 51. Intas Pharmaceuticals Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 52. Pfizer Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 53. Sandoz International Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 54. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 55. Apotex Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 56. BIOCAD Revenue Growth Rate in Oncology Biosimilars Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock